介入治疗膜部室间隔缺损的疗效初评

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (1): 78-80.

介入治疗膜部室间隔缺损的疗效初评

汤圣兴, 纪勤炯1, 朱向明², 张平洋², 曹蘅¹, 祈述善, 王安才¹

中南大学湘雅医学皖, 长沙 410078, 湖南; ¹南医学院弋矶山医院心内科; ²超声影像科, 芜湖 241001, 安徽

收稿日期:2002-08-23 修回日期:2002-09-04 发布日期:2020-11-25
通讯作者: 汤圣兴, 男, 副主任医师, 副教授, 中南大学湘雅医学院介入心脏病学博士研究生, 主要从事心脏介入治疗。Tel:0553-5738856 E-mail:tsx2229@163.com
作者简介:祈述善, 男, 教授, 博士生导师

Preliminary assessment of the efficiency of transcatheter closure of ventricular septal defects in membranous part

TANG Shen-Xing, JI Qing-Jiong¹, ZHU Xiang-Ming², ZHANG Ping-Yang², CAO Heng¹, QI Shu-Shan, WANG An-Cai²

Afflicated Xiangya Medical College, Center-South University; ¹Department of Cardiology, ²Echocariographic, Yijishan Hospital, Wannan Medical College, Wuhu 24100, Anhui

Received:2002-08-23 Revised:2002-09-04 Published:2020-11-25

摘要/Abstract

摘要： 目的: 评价介入治疗先天性心脏病室间隔缺损(VSD) 的初步疗效。方法: 2 例病人经食道超声(TEE) 证实为VSD, 并在透视和TEE 下置入封堵器。术后24 h、1 mon 经胸超声、心电图(ECG) 和X 线胸片检查评价治疗效果。结果: 2 例VSD 病人, 选择的封堵器的直径为4 mm 和6 mm。术中未发现任何并发症。术后即刻、24 h 和1 mon, 经胸B 超检查所有病例无残余分流和再通。结论: 经导管置入封堵器治疗VSD 是一种有效的微创方法, 其远期疗效需进一步观察。

关键词: 室间隔缺损, 介入治疗, 先天性心脏病

Abstract: AIM: To evaluate the efficiency of transcatheter closure of ventricular septal defects (VSD). METHODS: Two patents were treated by transcatheter closure.The cases of VSD were confirmed by transesophageal echocardiography (TEE) before treatment.Two cases were treated using occluder device through the percutaneous procedure under fluoroscopy and TEE.After the procedure, TEE and fluoroscopy were performed immediately to find whether any residual shunt was remained. RESULTS: Values of the occluder diameter selected were 4 and 6mm in the two cases, respectively.No complications occurred during the procedure, and no residual shunt and recanalization were found after 24 h and 1 mon. CONCLUTION: Transcatheter closure of VSD using the occluder is an efficient microinvasive method, but further results will obtain from a long term observation.

Key words: ventricular septal defects, transcatheter closure, congenital heart disease

中图分类号:

R459.9

汤圣兴, 纪勤炯1, 朱向明, 张平洋, 曹蘅, 祈述善, 王安才. 介入治疗膜部室间隔缺损的疗效初评[J]. 中国临床药理学与治疗学, 2003, 8(1): 78-80.

TANG Shen-Xing, JI Qing-Jiong, ZHU Xiang-Ming, ZHANG Ping-Yang, CAO Heng, QI Shu-Shan, WANG An-Cai. Preliminary assessment of the efficiency of transcatheter closure of ventricular septal defects in membranous part[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 78-80.

[1]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[2]	陈力方, 王博, 王维蓉. 组蛋白去乙酰化酶3在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 88-97.
[3]	何胜虎，周胜华，张晶,王雪飞,王大新. 急性ST段抬高型心肌梗死急诊PCI发生恶性心律失常临床特点及替罗非班的影响[J]. 中国临床药理学与治疗学, 2016, 21(4): 432-435.
[4]	章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.
[5]	李益民, 黄进, 陆治平, 李翔宇, 何胜虎. 替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响[J]. 中国临床药理学与治疗学, 2014, 19(12): 1403-1406.
[6]	周勇, 黄松群, 徐飞. 术前与术中使用替罗非班对急性ST段抬高心肌梗死急诊介入治疗慢血流的比较及安全性[J]. 中国临床药理学与治疗学, 2014, 19(11): 1268-1271.
[7]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.
[8]	高儒雅, 张亚同, 曹国颖. 北京医院经皮冠状动脉介入治疗前后用药情况和建议[J]. 中国临床药理学与治疗学, 2013, 18(10): 1110-1115.
[9]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J]. 中国临床药理学与治疗学, 2012, 17(9): 1074-1080.
[10]	邓少雄, 郭南鸥, 郑渊, 黄文森. 替罗非班对急性ST段抬高型心肌梗死并糖尿病患者急诊经皮冠状动脉介入治疗术后血清MMP-9水平的影响及临床意义[J]. 中国临床药理学与治疗学, 2011, 16(7): 807-811.
[11]	邓少雄, 郑渊, 郭南鸥. 阿托伐他汀对急性心肌梗死冠脉介入治疗术后的疗效及再狭窄的影响[J]. 中国临床药理学与治疗学, 2010, 15(2): 199-203.
[12]	汤圣兴, 纪勤炯, 张平洋, 朱向明, 曹蘅, 钱广玲, 王安才. 介入治疗动脉导管未闭和房间隔缺损及其疗效评价[J]. 中国临床药理学与治疗学, 2002, 7(5): 431-433.
[13]	陈绍良, 段宝祥, 叶飞, 方五旺, 胡作英, 黄进, 戴震林, 周陵, 罗俊, 林松, 查铭凡, 耿其吉. 冠状动脉介入治疗促进血管内皮素Ⅰ和血管紧张素Ⅱ的释放[J]. 中国临床药理学与治疗学, 2001, 6(4): 301-306.